Inside the research
Prestige Consumer Healthcare Inc.
PBH Research profile · latest available data
Price overview
$46.61
▲ +0.96 (+2.1%)
| 52w hi | $70.21 |
|---|---|
| 52w lo | $44.97 |
| Vol | 467.70K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.24
| Short | -0.38 |
|---|---|
| Medium | -0.17 |
| Long | -0.11 |
computed 2026-09-27
Key fundamentals
Prestige Consumer Healthcare Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $2.21B |
|---|---|
| Enterprise value | $4.19B |
| Trailing P/E | 13.06x |
| Forward P/E | 9.17x |
| EV / EBITDA | 12.87x |
| P / S (ttm) | 2.00x |
| Profit margin | 15.6% |
| Return on equity | 9.1% |
| Revenue growth | +6.5% |
| Earnings growth | -35.8% |
| Debt / equity | 107.86 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.14 | |
| Sector | +0.08 | |
| Technical | -0.28 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Risk Metrics
| Beta vs SPX | 0.39 |
|---|---|
| Corr SPX | 0.20 |
| Annual vol | 30.4% |
| Annual ret | -17.8% |
| Sharpe | -0.59 |
| Max DD | -49.5% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-14 | Officer / Director Change | read |
| 2026-08-06 | Earnings Release, Reg FD Disclosure… | read |
| 2026-07-15 | Material Agreement, Material Obligation… | read |
| 2026-07-06 | Material Agreement, Material Obligation… | read |
| 2026-06-16 | Material Agreement, Acquisition / Disposition… | read |
| 2026-05-13 | Material Agreement, Earnings Release… | read |
| 2026-03-20 | Material Agreement, Reg FD Disclosure… | read |
| 2026-02-05 | Earnings Release, Reg FD Disclosure… | read |
| 2025-11-06 | Earnings Release, Reg FD Disclosure… | read |
| 2025-08-07 | Material Agreement, Earnings Release… | read |
| 2025-05-08 | Earnings Release, Reg FD Disclosure… | read |
| 2025-02-06 | Earnings Release, Reg FD Disclosure… | read |
SEC Filings
The Long Run
FY 2011–2026 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.13B | +9.0% | |
| Gross profit | $624.45M | +10.5% | |
| Operating income | $309.41M | +8.2% | |
| Net income | $209.34M | +17.8% | |
| Cash from ops | $257.63M | +10.0% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $45.34 | $46.72 | $44.97 | $46.61 | 467.70K |
| Sep 24 | $46.12 | $46.49 | $45.30 | $45.65 | 627.20K |
| Sep 23 | $47.45 | $47.46 | $45.91 | $45.92 | 503.90K |
| Sep 22 | $47.55 | $47.80 | $47.02 | $47.73 | 619.60K |
| Sep 21 | $45.01 | $47.00 | $44.46 | $46.80 | 660.40K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →